In conclusion, PD-1/PD-L1 inhibitors in combination with chemotherapy and lenvatinib are both beneficial to tumor control and survival extension as first-line treatment in advanced ICC patients, with no severe adverse events. The gene discussed is CD274; the disease is neoplasm.